DNA methylation in neuroblastic tumors

Barbara Banelli, Angela Di Vinci, Ilaria Gelvi, Ida Casciano, Giorgio Allemanni, Stefano Bonassi, Massimo Romani

Research output: Contribution to journalArticle

Abstract

Epigenetic modifications and particularly the methylation of cytosines 5′ of guanine residues (CpGs) in gene promoter regions is an essential regulatory mechanism for normal cell development. DNA methylation can inactivate tumor suppressor genes by inducing C>T transitions in somatic and germline cells and by altering gene transcription. On the other hand, hypomethylation of specific sequences may reactivate the expression of potential oncogenes. Thus, aberrant hyper- and hypomethylation are considered crucial steps leading to cancer development. Until recently, differently from most adult tumors, only limited information was available on the methylation aberrations in neuroblastoma. In the last 2 years, however, this situation has drastically changed and many information has been gained on the relevance of methylation in this tumor. In this review, we summarize the latest findings on the role of methylation in neuroblastoma and in particular to its clinical significance.

Original languageEnglish
Pages (from-to)37-41
Number of pages5
JournalCancer Letters
Volume228
Issue number1-2
DOIs
Publication statusPublished - Oct 18 2005

Keywords

  • Epigenetics
  • Methylation
  • Prognostic factors

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Fingerprint Dive into the research topics of 'DNA methylation in neuroblastic tumors'. Together they form a unique fingerprint.

  • Cite this

    Banelli, B., Di Vinci, A., Gelvi, I., Casciano, I., Allemanni, G., Bonassi, S., & Romani, M. (2005). DNA methylation in neuroblastic tumors. Cancer Letters, 228(1-2), 37-41. https://doi.org/10.1016/j.canlet.2005.02.049